Free tool
FAERS Monitor: Zevtera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218275 or its brand name (Zevtera, Ceftobiprole Medocaril Sodium). Reports on generic versions are filed under their own applications.
Reports
57
Serious
55
96% of reports
Hospitalization
26
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use12
- epilepsy10
- torsade de pointes6
- alveolar lung disease5
- gangrene5
- pneumonia necrotising5
- rash5
- agitation3
- clostridium difficile infection3
- diarrhoea3
- pancytopenia3
- pruritus3
- pyrexia3
- alanine aminotransferase increased2
- anaemia2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 10 |
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 3 |
| 2025 | 19 |
| 2026 | 22 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,102 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| alveolar lung diseaseSignal | 5 | 9983.0 | 4268.9 | 39,359 |
| pneumonia necrotisingSignal | 5 | 2876.7 | 1240.9 | 11,552 |
| gangreneSignal | 5 | 306.4 | 132.6 | 1,231 |
| torsade de pointesSignal | 6 | 282.5 | 132.5 | 1,413 |
| epilepsySignal | 10 | 120.7 | 68.8 | 1,072 |
| clostridium difficile infectionSignal | 3 | 50.7 | 16.9 | 101 |
| pancytopeniaSignal | 3 | 19.8 | 6.6 | 37 |
| agitationSignal | 3 | 15.1 | 5.0 | 27 |
| alanine aminotransferase increased | 2 | 12.0 | 3.1 | 11 |
| off label useSignal | 12 | 5.1 | 3.1 | 37 |
| rashSignal | 5 | 4.2 | 1.8 | 10 |
| anaemia | 2 | 3.9 | 1.0 | 2 |
| pyrexia | 3 | 3.2 | 1.1 | 3 |
| pruritus | 3 | 2.9 | 1.0 | 2 |
| diarrhoea | 3 | 1.7 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.